U.S. markets closed
  • S&P Futures

    3,647.00
    +23.75 (+0.66%)
     
  • Dow Futures

    29,781.00
    +152.00 (+0.51%)
     
  • Nasdaq Futures

    12,376.25
    +99.25 (+0.81%)
     
  • Russell 2000 Futures

    1,836.70
    +16.60 (+0.91%)
     
  • Crude Oil

    45.05
    -0.29 (-0.64%)
     
  • Gold

    1,782.80
    +1.90 (+0.11%)
     
  • Silver

    22.73
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1953
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3346
    +0.0014 (+0.11%)
     
  • USD/JPY

    104.3550
    +0.0310 (+0.03%)
     
  • BTC-USD

    19,566.47
    +69.62 (+0.36%)
     
  • CMC Crypto 200

    384.39
    +19.79 (+5.43%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,773.75
    +340.13 (+1.29%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of NNOX, GOCO and BMRN

·4 min read

NEW YORK, NY / ACCESSWIRE / October 20, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Nano-X Imaging Ltd. (NASDAQ: NNOX)

Investors Affected : August 21, 2020 - September 15, 2020

A class action has commenced on behalf of certain shareholders in Nano-X Imaging Ltd. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/nano-x-imaging-ltd-loss-submission-form/?id=10295&from=1

GoHealth, Inc. (NASDAQ: GOCO)

The GoHealth lawsuit is on behalf of all purchasers of GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth's July 2020 initial public offering.

A class action has commenced on behalf of certain shareholders in GoHealth, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (iii) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company's concentrated carrier business model, and GoHealth's efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (iv) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (v) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the initial public offering.

Shareholders may find more information at https://securitiesclasslaw.com/securities/gohealth-inc-loss-submission-form/?id=10295&from=1

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

Investors Affected : February 28, 2020 - August 18, 2020

A class action has commenced on behalf of certain shareholders in BioMarin Pharmaceutical Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/biomarin-pharmaceutical-inc-loss-submission-form/?id=10295&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/611283/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-NNOX-GOCO-and-BMRN